Skip to content


    DEA Class;  Rx

    Common Brand Names; Latuda

    • Antipsychotics, 2nd Generation; 
    Oral atypical antipsychotic; belongs to benzisoxazole/benzoisothiazol derivative class
    Used for schizophrenia in adults and adolescents and for bipolar I depression in adult and pediatric patients 10 years and older
    Contraindicated with strong CYP3A4 inhibitors or inducers; as with all antipsychotics, boxed warning for increased mortality risk in elderly patients with dementia-related psychosis
    Indicated for the treatment of refractory schizophrenia that has failed to respond adequately to appropriate courses of standard antipsychotic agents; also to reduce the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder.
    For the treatment of bipolar disorder.


    Coadministration with strong CYP3A4 inhibitors (eg, ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil)

    Coadministration with strong CYP3A4 inducers (eg, rifampin, St. John’s wort, phenytoin, carbamazepine)

    • Somnolence, dose related (15-26%)
    • Akathisia, dose related (6-22%)
    • Extrapyramidal disorder, dose related (6-22%)
    • Parkinsonism, dose related (6-17%)
    • Fasting glucose increased, dose related (10-14%)
    • Nausea, dose related (9-13%)
    • Insomnia, dose-related (7-11%)
    • Agitation, dose related (3-10%)
    • Vomiting, dose related (6-8%)
    • Dyspepsia, dose related (5-8%)
    • Anxiety, dose related (3-8%)
    • Elevated serum creatinine, dose related (1-7.2%)
    • Dystonia (5%)
    • Dizziness, dose related (4-6%)
    • Fatigue (4%)
    • Back pain, dose related (2-4%)
    • Restlessness (3%)
    • Salivary hypersecretion, dose related (1-4%)
    • Hypertension
    • Rash
    • Pruritus
    • CPK increased
    • Abdominal pain
    • Diarrhea
    • Blurred vision
    • Tachycardia
    • Anemia
    • AV block 1st degree
    • Angina pectoris
    • Bradycardia
    • Vertigo
    • Gastritis
    • Rhabdomyolysis
    • Cerebrovascular accident
    • Dysarthria
    • Abnormal dreams
    • Panic attack
    • Sleep disorder
    • Dysuria
    • Renal failure
    • Amenorrhea
    • Dysmenorrhea
    • Breast enlargement
    • Breast pain

    Possibility of suicide attempt inherent to psychotic illness; close supervision required when therapy is initiated, dosage is changed, or drug is discontinued; the risk of suicidal thoughts and behaviors in pediatric and young adult patients extends to longer-term use (eg, >4 months) is unknown; there is substantial evidence from placebo-controlled maintenance studies in adults with MDD that antidepressants delay the recurrence of depression

    Antidepressant treatment can increase the risk of developing a manic or hypomanic episode, particularly in patients with bipolar disorder

    Patients with Parkinson’s disease or dementia with Lewy bodies are reported to have an increased sensitivity to antipsychotic medication

    Orthostatic hypotension and syncope reported, possibly due to its alpha-1receptor antagonism

    Risk of neuroleptic malignant syndrome (NMS) reported in association with administration of antipsychotic drugs, including lurasidone; clinical manifestations of NMS (eg, hyperpyrexia, muscle rigidity, altered mental status, evidence of autonomic instability); additional symptoms (eg, elevated creatine phosphokinase, myoglobinuria [rhabdomyolysis], acute renal failure); the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses or may even arise after discontinuation of treatment; if NMS is suspected, immediately discontinue therapy and provide intensive symptomatic treatment and monitoring

    Hyperprolactinemia reported; galactorrhea, amenorrhea, gynecomastia, and impotence reported with prolactin-elevating compounds; long-standing hyperprolactinemia, when associated with hypogonadism, may lead to decreased bone density in both female and male patients

    Neonates exposed to antipsychotic drugs during 3rd trimester of pregnancy are at risk for extrapyramidal symptoms (EPS) and/or withdrawal symptoms after delivery

    Unknown whether drug is distributed in breast milk

    Lurasidone is present in rat milk

    Consider development and health benefits of breastfeeding along with mother’s clinical need for drug and any potential adverse effects on breastfed infant from therapy or from underlying maternal condition


    160 mg/day PO.


    160 mg/day PO.


    80 mg/day PO.


    10 years and older: 80 mg/day PO.
    Less than 10 years: Safety and efficacy have not been established.


    Not indicated.

    Lurasidone hydrochloride


    • 20mg
    • 40mg
    • 60mg
    • 80mg
    • 120mg